Huons, a subsidiary of Huons Global, said Monday that it would enhance its facility in Jecheon, North Chungcheong Province, to expand its share in the global eye drop market.

The company plans to install nine types of machinery, including a blow-fill-seal system and a foreign body inspection machine from Rommelag, a German company. The adoption of the new equipment is a strategy to preempt the global market while increasing productivity and quality for domestic demand and export volume in the future. Huons plans to install the system by October.

Although Rommelag equipment is expensive than most conventional equipment, it satisfies both European and U.S. regulatory standards. The company expects the new machinery will equip them with essential qualifications to cope with exports, making it easier to enter the advanced pharmaceutical market in the future.

After finishing their installment, the eye drop production capacity is set to increase from the current 1.5 million to 3 million units.

The upgrade of its factory comes amid the company receiving clinical trial approval from China’s Food and Drug Administration for Clacier eye drop. The company also forecasts the new improvement on its plant will stabilize supply for its previous contract with three Central and South America countries, Saudi Arabia and other Middle Eastern countries.

“The company decided to introduce cutting-edge equipment as a preemptive investment to cope with the rapidly growing eye drop market,” Huons CEO Um Key-an said. “By upgrading its facilities, Huons will be able to maintain both high productivity and competitive quality.”

Huons has registered patents for Clacier, a cyclosporine single nano eye drop, and Kaynex, a single hyaluronic acid eye drop, in the U.S., Australia, Russia and Europe.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>